Semaglutide constipation: Causes and relief
GLP-1 Drugs and Risks for Postmenopausal Women Older women have a few extra factors to consider when they begin taking a GLP-1 drug
Classified obesity as a chronic disease requiring long-term carenot a quick fix, explains John
This article from 2015 does a good job conveying the boom-bust cycle around miracle weight loss drugs pre GLP-1s, and the resulting skepticism with which the medical establishment viewed the category
Key Growth Trends: Increasing acquisitions Pharmaceutical developments Major Challenges: Limited clinical evidence Higher production costs Key Players: Post Holdings, GNC, Nature's Way, Nature's Bounty, NOW, and more
4-Week Semaglutide Microdosing Program with Consultation Designed for people with a BMI between 2025 who may not be traditional candidates for GLP-1s